Место валсартана в современной гипотензивной и нефропротективной терапии


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Хроническая болезнь почек - независимый фактор риска развития сердечно-сосудистых событий у пациентов с артериальной гипертензией. Применение валсартана не только обеспечивает адекватный контроль артериального давления и высокий уровень органопротекции, но и уменьшает сердечно-сосудистый риск.

Полный текст

Доступ закрыт

Об авторах

О. Дралова

Первый МГМУ им. И.М. Сеченова

Email: olgadralova@rambler.ru

Список литературы

  1. Tonelli М., Wiebe N., Culleton B. et al. Chronic Kidney Disease and Mortality Risk: A Systematic Review // JASN/ - 2006; 17: 2034-47.
  2. Кобалава Ж.Д., Ефремовцева М.А. Комбинированная антигипертензивная терапия у пациентов с АГ и хронической нефропатией // Сердце: журнал для практикующих врачей. - 2005; 3: 138-40.
  3. Терещенко С.Н., Демидова И.В. Почечная функция при хронической сердечной недостаточности у больных пожилого и старческого возраста // Сердце: журнал для практикующих врачей. - 2002; 5: 251-8.
  4. Penegrer T., Klag M., Feldman H. et al. Projections of hypertension-related renal disease in middle-aged residents of the United States // JAMA. - 1993; 269: 1272-7.
  5. Martinez M., Moreno A., Aguirre A. et al. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study // J. Hypertension. - 2001; 19: 319-26.
  6. K/DOQ1 clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease //Am. J. Kidney Dis. - 2004; 43 (5): 1-290.
  7. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertension. doi: 10.1097/01.hjh.0000431740.32696.cc
  8. Диагностика и лечение артериальной гипертензии. Российские рекомедации (4-й пересмотр) // Системные гипертензии. - 2010; 3: 5-26.
  9. Peterson J., Adler S., Burkart J. et al. Blood pressure control, proteinuria, and the progression of renal disease // Ann. Int. Med. - 1995; 123: 754-62.
  10. USRDS: U.S. Renal Data System. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the nited States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002. In Edition.
  11. Sarnak M., Levey A., Schoolwerth A. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention // Hypertension. - 2003; 42: 1050-65.
  12. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension // J. Hypert. - 1999, 17:151-83.
  13. Meyrier A., Simon P. Nephroangiosclerosis and hypertension: things are not as simple as you might think // Nephrol. Dial. Transplant. - 1996; 11: 2116-20.
  14. Ritz E., Orth S., Weinreich T. et al. Systemic hypertension versus intraglomerular hypertension in progression // Kidney Int. - 1994; 45: 438-42.
  15. Luke R. Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease // Nephrol. Dial. Transplant. - 1999; 14: 2271-8.
  16. Remuzzi A., Gagliardini E., Donadoni C. et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat // Kidney Int. - 2002; 62: 885-94.
  17. Remuzzi G., Perico N., Macia M. et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease // Kidney Int. Suppl. - 2005; 99: 57-65.
  18. Brenner B. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease // Kidney Int. - 1983; 23: 647-55.
  19. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease // Nephrol. Dial. Transplant. - 1999; 14 (1): 42-4.
  20. Томилина Н.А., Багдасарян А.Р. Механизмы нефросклероза и фармакологическая ингибиция внутри почечной ренин-ангиотензиновой системы как основа нефропротективной стратегии при хронических заболеваниях нативных почек и почечного трансплантата (Обзор литературы) // Нефрология и диализ. - 2004; 6 (3): URL: http://www.nephro.ru/magazine/article.php?id=15288
  21. Шестакова М.В. Современные возможности нефропротекции при артериальной гипертензии и сахарном диабете // Сердце: журнал для практикующих врачей. - 2004; 1: 23-5.
  22. Николаев А.Н. Прогрессирование почечной недостаточности : Участие ATI-рецептора // РМЖ. - 2001; 24: 1136-7.
  23. Goodfriend T., Elliott M., Catt K. Angiotensin receptors and their antagonists // N. Engl. J. Med. - 1996; 334: 1649-54.
  24. Mancia G. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart. J. - 2013; [e-pub ahead of print] http://dx.doi.org/10.1093/ eurheartj/eht151.
  25. Prevot A., Mosig D., Guignard J. The effects of losartan on renal function in the newborn rabbit // Pediatr. Res. - 2002; 51 (6): 728-32.
  26. Nishijama K., Igari T., Nanda S. et al. Long-term effects of delapril on renal function annd urinary excretion of kallikrein, prostaglandin E2, and thromboxan B2 in hypertensive patients // Am. J. Hypertens. - 1991; 4: 52-3.
  27. Levey A., Coresh J., Balk E. et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification // Ann. Int. Med. - 2003; 139: 137-47.
  28. Gu C., Zhou G., Noble N. et al. Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect ofvalsartan by protecting podocytes // J. Renin Angiotensin Aldosterone Syst. - 2012 Dec 4. [Epub. ahead of print].
  29. Brenner B., Cooper M., de Zeeuw D. et al. Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) // JRAAS. - 2000; 1: 328-35.
  30. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial // Lancet. - 2003; 361: 117-24.
  31. Iino Y., Hayashi M., Kawamura T. et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study // Hypertens Res. -2004; 27: 21-30.
  32. Opie L., Parving H.-H. Diabetic nephropathy. Can renoprotection be extrapolated to cardiovascular protection? // Circulation. - 2002; 106: 643-5.
  33. Andersen N., Poulsen P., Knudsen S. et. al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study // Diabetes Care. - 2005; 28 (2): 273-7.
  34. Burgess E., Muirhead N., Rene de Cotret P. et al. SMART (Supra MaximalAtacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease // J. Am. Soc. Nephrol. - 2009; 20 (4): 893-900.
  35. Barnett A., Bain S., Bouter P. et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy // N. Engl. J. Med. - 2004; 351 (19): 1952-61.
  36. Makino H., Haneda M., Babazono T. et al. For the INNOVATION Study Group. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study // Hypertens Res. - 2008; 31 (4): 657-64.
  37. Schmieder R., Delles C., Mimran A. et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes // Diabetes Care. - 2007; 30: 1351-6.
  38. Чудновская Е.А., Струтынский А.В. Применение блокаторов АТ1-рецепторов ангиотензина в патогенетической терапии артериальной гипертензии // РМЖ. - 2004; 12: 727-32.
  39. Швецов М.Ю. и др. Опыт пpименения валсаpтана с целью тоpможения пpогpессиpования почечной недостаточности у больных хpоническим гломеpулонефpитом // Тер. арх. - 2001; 6: 55-61.
  40. Viberti G., Wheeldon N. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect // Circulation. - 2002; 106: 672-8.
  41. Suzuki K., Souda S., Ikarashi T. et al. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy // Diabet. Res. Clin. Pract. - 2002; 57 (3): 179-83.
  42. Uzu T. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART) // Diabet. Care - 2007; 30: 1581-3.
  43. Takano H., Hasegawa H., Narumi H. et al. VART investigators. Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART // J. Hum. Hypertens. - 2012; 26 (11): 656-63.
  44. Hollenberg N., Parving H., Viberti G. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus // J. Hypertens. - 2007; 25: 1921-6.
  45. Zhang X., Ding X., Cao G. et al. Efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese patients with essential hypertension: a multicenter prospective open-label observational study // Curr. Med. Res. Opin. -2012; 28 (10): 1677-84.
  46. Galle J., Schwedhelm E., Pinnetti S. et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy // Nephrol. Dial. Transplant. - 2008; 23 (10): 3174-83.
  47. Amano K., Shiraishi J., Sawada T. et al. Enhanced cardio-renal protective effects of valsartan in high-risk hypertensive patients with chronic kidney disease: A sub-analysis of KYOTO HEART Study // Int. J. Cardiol. - 2012; pii: S0167-5273(12)00090-3. doi: 10.1016/j.ijcard.2012.01.072. [Epub. ahead of print]
  48. Yasuda T., Endoh M., Suzuki D. et al. KVT Study Group. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT) // Hypertens. Res. - 2013; 36 (3): 240-6.
  49. Greathouse M., Weir M. The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications // Postgrad. Med. - 2012; 124 (2): 40-52.
  50. Bilic M., Munjas-Samarin R., Ljubanovic D. et al. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria // Coll. Antropol. - 2011; 35 (4): 1061-6.
  51. Upadhyay A., Earley A., Haynes S., Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier // Ann. Int. Med. - 2011; 154: 541-8.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ИД "Русский врач", 2013